2024 Global Coagulation Testing Market

2024 Global Coagulation Testing Market in the US, Europe, Japan--Hemostasis Analyzers and Consumables--2023 Supplier Shares, 2023-2028 Segment Volume and Sales Forecasts for over 40 Coagulation Assays, Opportunities for Suppliers--Molecular, Chromogenic and Immunodiagnostic Hemostasis Tests--Growth Strategies, Latest Technologies, Instrumentation Pipeline

Summary

This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global coagulation testing market during the next five years.

The report is available by section, and can be customized to specific information needs and budget.

The report explores business and technological trends in the US, Europe (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

Rationale

The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromagenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, computers and laboratory automation will radically change the global coagulation diagnostics practice during the next five years.

New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.

Coagulation Tests Analyzed in the Report

Activated Clotting Time (ACT) (1), Activated Protein C Resistance, Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX, Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation, Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time, Von Willebrands Factor Fav/Ag, and others.

Geographic Coverage

France, Germany, Italy, Japan, Spain, UK, USA

Competitive Assessments

- Extensive strategic profiles of major suppliers and emerging market entrants.

Current and Emerging Products

- Review of established and emerging procedures.

- Comparison of automated and semi-automated analyzers marketed by Diagnostica Stago, Helena, IL, Siemens, Sysmex and other suppliers.

Technology Review

- Analysis of current and emerging technologies and their potential market applications.

- Companies developing or marketing new technologies and products by test.

Strategic Recommendations

- Product development and business expansion opportunities with significant market appeal.

- Ideal product models with tentative prices and operating characteristics.

- Alternative market penetration strategies for instrument and reagent suppliers.
- Potential market entry barriers and risks.

I. Introduction
II. Major Product Development Opportunities
III. Design Criteria For Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Market and Technology Overview
A. Major Routine and Special Coagulation Tests
1. Introduction
2. Activated Partial Thromboplastin Time (APTT)
3. Alpha-2 Antiplasmin
4. Antithrombin III
5. Bleeding Time
6. D-Dimer
7. Ethanol Flocculation Test
8. Euglobulin Lysis
9. Factor Assays
a. Introduction
b. Factor II
c. Factor V/Factor V Leiden
d. Factor VII
e. Factor VIII
f. Factor IX
g. Factor IXa
h. Factor X (Stuart Factor)
i. Factor Xa
j. Factor XI
k. Factor XII
l. Factor XIII

10. Fibrin Degradation Products
11. Fibrinogen
12. Heparin
13. Hirudin
14. Hypercoagulability and Thrombosis
15. Lipoprotein a
16. Plasmin
17. Plasminogen
18. Plasminogen Activator Inhibitor (PAI)
19. Platelet Function Tests
20. Platelet Aggregation
21. Proteins C and S
22. Prothrombin Fragment 1.2
23. Prothrombin Time (PT)
24. Reptilase Time
25. Thrombin Time
26. Tissue-Type Plasminogen Activator (t-PA)
27. Von Willebrands Factor
B. Coagulation Instrumentation Review: Centralized
and POC Testing Analyzers
C. Major Coagulation Testing Technologies
and Their Potential Applications
1. Chromogenic Substrates
2. Monoclonal and Polyclonal Antibodies
3. Immunoassays
4. Molecular Diagnostics
5. Microcomputers
6. Automation
7. Robotics
8. Artificial Intelligence
9. Dry Chemistry
10. Bisensors
VII. Country Market Size, Test Volume
and Sales Forecasts by Segment, Major
Instrument and Reagent Suppliers Market
Shares


VIII. Competitive Assessments
The report provides strategic assessments of over 20 leading coagulation market
players and start-up companies with innovative technologies and products,
including:
Abbott
Beckman Coulter/Danaher
Becton Dickinson
Diagnostica Stago
Grifols
Helena Laboratores
IL/Werfen
Roche
Sekisui Diagnostics
Siemens Healthineers
Sysmex
Thermo Fisher, and others

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available